Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.77, $0.09 better than the analyst estimate of $2.68. Revenue for the quarter came in at $23.74 billion versus the consensus estimate of $22.86 billion.

GUIDANCE:

Johnson & Johnson sees FY2025 EPS of $10.63-$10.73, versus the consensus of $10.61. Johnson & Johnson sees FY2025 revenue of $93.2-93.6 billion, versus the consensus of $91.3 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• KKR offered to buy UGI for $42.50 a share - WSJ
• UGI Corp. (UGI) halted on volatility, up 6%